Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Japanese Journal of Radiology|November 28, 2009
Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experienceTakefumi Satoh, Hiromichi Ishiyama, Kazumasa Matsumoto, et al.
Urologic Oncology|February 26, 2013
Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer modelsTetsuo Fujita, Takefumi Satoh, Terry L Timme, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 17, 2006
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancerGustavo Ayala, Takefumi Satoh, Rile Li, et al.
International Journal of Clinical Oncology|June 24, 2018
Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survivalKazuto Ito, Shiro Saito, Atsunori Yorozu, et al.
The Journal of Urology|September 28, 2002
The role of caveolin-1 in androgen insensitive prostate cancerVladimir Mouraviev, Likun Li, Salahaldin A Tahir, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|August 11, 2006
[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer]Ken-Ichi Tabata, Takefumi Satoh, Kazumasa Matsumoto, et al.
BJU International|December 2, 2008
Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysisTakefumi Satoh, Hiromichi Ishiyama, Kazumasa Matsumoto, et al.
European Urology|December 24, 2019
Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)<sup>†</sup>Akira Yokomizo, Masashi Wakabayashi, Takefumi Satoh, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2004
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patientsTakefumi Satoh, Bin S Teh, Terry L Timme, et al.
International Journal of Clinical Oncology|September 12, 2016
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trialTomomi Kamba, Toshiyuki Kamoto, Shinichiro Maruo, et al.
Pageof 14